awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q52647706-1F802274-69FF-4083-97B1-7286A875874E
Q52647706-1F802274-69FF-4083-97B1-7286A875874E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q52647706-1F802274-69FF-4083-97B1-7286A875874E
Comparison of chemotherapy plus bevacizumab vs. chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer: A propensity score-matched analysis.
P2860
Q52647706-1F802274-69FF-4083-97B1-7286A875874E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q52647706-1F802274-69FF-4083-97B1-7286A875874E
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
bc323e632ec0b9561af5c31958a496b47b261497
P2860
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.